RXi Pharmaceuticals (RXII) Hires Dr. Anastasia Khvorova as its First Chief Scientific Officer
RXi Pharmaceuticals Corporation (NASDAQ: RXII) reported today that it has hired Dr. Anastasia Khvorova to fill the new post of Chief Scientific Officer (CSO). RXi Pharmaceuticals expects to benefit from the six years of experience Khvorova gained in the development and supply of RNAi compounds in her last job as CSO of Dharmacon, Inc. According to company President and CEO, Dr. Tod Woolf, Khvorova’s appointment adds to the scope and depth of RXi’s talent in the RNAi field. "Among her many accomplishments,” noted Woolf, “Dr. Khvorova's group at Dharmacon designed and manufactured RNAi compounds targeting virtually all of the known…